BioXcel Therapeutics, Inc. (BTAI) earnings
BTAI earnings moved a median of -3.28% by the close. Quarterly and annual BTAI reports and results, each read against the price at its own news timestamp. Back to the BTAI overview →
24 measured BTAI earnings events.
Where these BTAI earnings landedvs 22 measured BTAI earnings reactions
| Middle 50% of BTAI earnings reactions | -6.43% to +1.10% |
|---|---|
| Median reaction (to close) | -3.28% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 BTAI earnings events with a measured close landed between -6.43% and +1.10%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q BioXcel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.91% | +7.21% | |
| BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | +1.28% | -2.56% | |
| Form 10-Q BioXcel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.28% | -2.56% | |
| Form 10-K BioXcel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -3.13% | -5.47% | |
| BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease | Press release | +0.55% | -6.56% | |
| Form 10-Q BioXcel Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.55% | -6.56% | |
| BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates | Press release | -1.78% | — | |
| Form 10-Q BioXcel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.56% | — | |
| BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -5.66% | -6.92% | |
| Form 10-Q BioXcel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -5.66% | -6.92% | |
| Form 10-K BioXcel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -7.21% | -0.98% | |
| BioXcel Therapeutics Reports Third Quarter 2024 Financial Results | Press release | -1.95% | -17.04% | |
| Form 10-Q BioXcel Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.95% | -17.04% | |
| BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 | Press release | -1.31% | -1.31% | |
| BioXcel Therapeutics Reports Second Quarter 2024 Financial Results | Press release | +2.00% | -4.00% | |
| Form 10-Q BioXcel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.00% | -4.00% | |
| BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024 | Press release | -0.86% | -6.03% | |
| BioXcel Therapeutics Reports First Quarter 2024 Financial Results | Press release | +2.61% | +1.10% | |
| Form 10-Q BioXcel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +2.61% | +1.10% | |
| BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 | Press release | -0.73% | -4.04% | |
| Form 10-K BioXcel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +7.31% | +9.62% | |
| BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results | Press release | +1.71% | +20.57% | |
| Form 10-Q BioXcel Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.71% | +20.57% | |
| BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023 | Press release | -2.86% | +2.42% |
Keep exploring
More BTAI: analyst actions → · SEC filings → · BTAI overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OHR PHARMACEUTICALS (OHRP) | 393 | 0.00% | 48% |
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.